StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 6.5
Power Rank trend -> Falling
03/27/2025 16:05:00 EST
Johnson & Johnson (JNJ)
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, JNJ has been trading in a range between $167.70 and $162.81 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
JNJ is trading between resistance at $163.22 about 0% to the upside and support at $159.53 -2% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $167.70, about a 3% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Johnson & Johnson $JNJ entered a Green zone 60 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $171.6109, a potential upside of 6.12% from the recent price of 161.72. The stock is trading 5.11% (potential upside) below its 52 week high of $169.99 and 16.61 % (potential downside) above its 52 week low of $138.68 - based on the recent price.
Company Summary
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
News
| Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector. Source: Market Watch Thu, 27 Mar 2025 10:22:00 -0400 Sentiment: Negative |
| How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern. Source: Investors Business Daily Thu, 27 Mar 2025 10:13:04 -0400 Sentiment: Negative |
| Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store. Source: Zacks Investment Research Thu, 27 Mar 2025 10:05:24 -0400 Sentiment: Positive |
| 2 Recession-Proof Dividend Stocks to Buy and Hold Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen. Source: The Motley Fool Thu, 27 Mar 2025 05:25:00 -0400 Sentiment: Neutral |
| Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets, aiming to generate sustainable dividend income and reduce portfolio volatility. Recent additions like Canadian Natural Resources and NextEra Energy enhance dividend growth potential and diversify sector allocation, reducing Financials Sector concentration. The portfolio boasts a Weighted Average Dividend Yield [FWD] of 3.98% and a 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.82%, ensuring attractive income and growth. Source: Seeking Alpha Wed, 26 Mar 2025 18:00:00 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 169.99 52 Week Low: 138.681 Beta: 0.463 50 Day MA: 158.1352 200 Day MA: 156.1321 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.034 Qtr Revenue Growth YOY: 0.053 Forward PE: 15.4083 Trailing PE: 28.1744